- Company
- What are the chances of Dovprela's successful benefits?
- by Eo, Yun-Ho Sep 5, 2022 05:55am
- Attention is focusing on whether the new tuberculosis drug Dovprela, which appeared in 50 years, can be listed on the insurance benefit list. According to related industries, Viatris Korea's Dovprela passed the HIRA Pharmaceutical Benefit Evaluation Committee on the 1st. Dovprela, which was approved in Korea in October last year after U.S.
- Company
- It has been a year since the release of Leclaza
- by Chon, Seung-Hyun Sep 5, 2022 05:55am
- Korea's first new anti-cancer drug is expected to generate 10 billion won in annual sales. Leclaza, a new anti-cancer drug developed by Yuhan Corporation, surpassed 10 billion won in cumulative sales within a year of its release in Korea. It showed a smooth move in the early stages of its release and predicted that it would surpass 10 billion
- Company
- Vyndamax is finally a step towards benefits
- by Eo, Yun-Ho Sep 2, 2022 06:03am
- Transthyretin cardiomyopathy new drug Vyndamax has finally made progress. According to related industries, Vyndamax, a treatment for ATTR-CM (ATTR amyloidosis with cardiomyopathy) caused by Transthyretin amyloidosis in Pfizer, recently passed the HIRA Pharmaceutical Benefit Standards Subcommittee. This is the result of his fourth attempt. As
- Company
- Q2 sales of Nexavar and Lenvima both sluggish
- by Kim, Jin-Gu Sep 2, 2022 06:03am
- Sales of all major liver cancer treatments are on the decline. Sales of Nexavar (sorafenib), which had dominated the first-line treatment market for liver cancer for over a decade, is on a continuous decline since the entry of its generics, and sales of Nexavar’s main competitor Lenvima have also been shown to be slowing down recently
- Company
- Japan first approved AZ Evusheld as Coronavirus tx
- by Sep 2, 2022 06:02am
- Japan approved AstraZeneca's long-lasting antibody complex Evusheld for the first time in the world for COVID-19 treatment. On the 30th (local time), Ministry of Health, Labour and Welfare of Japan approved the Evusheld as a prevention of symptomatic diseases caused by COVID-19 infection (pre-exposure prophylactic therapy) and a treatment for
- Company
- Trelegy Ellipta lands in Big 5 tertiary hospitals in Korea
- by Eo, Yun-Ho Sep 1, 2022 05:56am
- The COPD treatment ‘Trelegy Ellipta’ has landed in general hospitals in Korea. The company has been making rapid entry into the market since its reimbursed release in June this year. According to industry sources, GSK Korea’s triple inhaled therapy for COPD (Chronic Obstructive Pulmonary Disease), “Trelegy Ellipta (fluticasone·umecli
- Company
- Imported shingles vaccine that has been suspended & delayed
- by Sep 1, 2022 05:56am
- The imported shingles vaccine is in short supply. This is because MSD's Zostavax has been out of stock for a while and the introduction of Shingrix, which was approved last year, continues to be delayed. According to the pharmaceutical industry on the 31st, Zostavax has been out of stock for about two months. MSD, which announced the news of
- Company
- Piqray can be prescribed in 18 hospitals
- by Eo, Yun-Ho Aug 30, 2022 05:54am
- Piqray, an anticancer drug targeting the PIK3CA gene, can be prescribed at a general hospital. According to related industries, Novartis' Piqray passed the Drug Committee of 18 medical institutions nationwide, including Samsung Medical Center, Seoul St. Mary's Hospital, and Seoul Asan Medical Center, as well as Bundang Medical Center and K
- Company
- HIV tx Delstrigo is available in major national hospitals
- by Eo, Yun-Ho Aug 29, 2022 06:03am
- The HIV complex Delstrigo is available in general hospitals. According to related industries, Delstrigo, a fixed-dose HIV tx taken once a day by MSD Korea, has passed the D.C. of medical institutions such as Sinchon Severance Hospital, National Medical Center, Pusan National University, Kyungpook National University, Chonnam National Univer
- Company
- Pfizer Korea receives tax audit...files tax appeal
- by Aug 29, 2022 06:03am
- On why Pfizer Korea filed a “tax appeal” against the National Tax Service, the company said it had “duly instituted administrative procedures, judging that some of the imposed taxation standards were unreasonable,” refuting the allegations that the company was fined due to ‘cost overstatements.’ According to the pharmaceutical indus
